The agentic AI execution
system built for life sciences.

An accelerator is "a prebuilt, domain-trained pharma workflow that installs into your stack" — not another login or generic chatbot. Each addresses specific problems like field voice capture, MSL insights, or launch planning, composed from reusable agents following a compounding model.

"Improzo's agentic platform, the orchestration and governance layer our accelerators run on." It connects authorized data sources to CRM, HRIS, ERP, and dashboards while governing orchestration, compliance checks, traceability, and offers "Ask iZO," a natural language interface for governed data interaction.

Improzo delivers accelerators across six areas: Voice Intelligence, Field & Engagement AI, Launch & Forecasting AI, Brand Intelligence, Medical Insights & Decisioning, and Market Research AI — collectively capturing signals, structuring intelligence, routing actions, and governing outputs.

"Yes. We work with your existing partners, not against them." Accelerators plug into existing landscapes rather than competing, allowing value from current relationships to compound instead of being displaced.

"No on both counts. Your data is yours, it does not need to move, and we do not train on it." Improzo connects to authorized data sources without replication, warehousing, or model training on client data.

They were protecting against architectures Improzo avoids. The platform includes "access governed by role and authorization," "source traceability on every output," "audit logs and human review," and "guardrails configured to your policies."

"Yes. Governance is built into every accelerator, not added afterward." Outputs route through compliance checks, pharmacovigilance detection, off-label gates, traceability, human review, and role-based access with full audit logging.

"You do." Intelligence runs on client data, inside their environment, under their governance, so outputs and operating value belong to them. Improzo provides accelerators and agents.

Start with one bounded workflow with clear ownership and success metrics — no finished strategy required. "The first accelerator is typically live in four to six weeks, and each one after in one to three weeks." The model follows: deploy, trust, expand.

Success combines measurable operating outcomes (time saved, lowered risk, quality, speed), real adoption in daily workflows, and governance-approved outputs. Results include "130% net revenue retention," "100% customer retention," and "60 to 80% productivity gains and 35 to 37% cost savings."

"No on both fronts." Business and medical teams run accelerators; Improzo can operate them in fully managed mode. "There is no platform tax, no per-seat sprawl, and no new system of record." Pricing ties to execution delivered, not seat counts.

Founded by Inderpreet Kambo and Abhishek Trigunait, the team includes leaders from IQVIA, ZS, Veeva, and pharma operations. "The name says the rest. Improzo combines Improve and Zo, the Greek word for life." The mission: improving life by empowering customers through closing the insight-to-execution gap.